Dr. Reddy's Laboratories Ltd (DRREDDY) - Financial and Strategic SWOT Analysis Review
Dr. Reddy's Laboratories Ltd (DRREDDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars and proprietary products. The company’s generic products are indicated for the treatment of gastrointestinal disorders, various cancer types, cardiovascular diseases, pain, central nervous system disorders, infectious diseases and pediatric diseases. The company also develops and markets generic biosimilar products. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.
Dr. Reddy's Laboratories Ltd Key Recent Developments
Sep 06,2021: Dr Reddy’s agrees to transfer rights of anti-cancer assets to Citius
Aug 03,2021: Dr. Reddy’s announces the re-launch of over-the-counter naproxen sodium tablets USP, 220 mg, store-brand equivalent of aleve in the U.S. Market
Jul 27,2021: Dr. Reddy’s announce Q1 FY22 Financial Results
Jul 27,2021: Dr. Reddy’s Q1 FY22 financial results
Jul 27,2021: Dr Reddys Laboratories Unaudited Financial Results For The Quarter Ended June 30, 2021
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars and proprietary products. The company’s generic products are indicated for the treatment of gastrointestinal disorders, various cancer types, cardiovascular diseases, pain, central nervous system disorders, infectious diseases and pediatric diseases. The company also develops and markets generic biosimilar products. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.
Dr. Reddy's Laboratories Ltd Key Recent Developments
Sep 06,2021: Dr Reddy’s agrees to transfer rights of anti-cancer assets to Citius
Aug 03,2021: Dr. Reddy’s announces the re-launch of over-the-counter naproxen sodium tablets USP, 220 mg, store-brand equivalent of aleve in the U.S. Market
Jul 27,2021: Dr. Reddy’s announce Q1 FY22 Financial Results
Jul 27,2021: Dr. Reddy’s Q1 FY22 financial results
Jul 27,2021: Dr Reddys Laboratories Unaudited Financial Results For The Quarter Ended June 30, 2021
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Dr. Reddy's Laboratories Ltd - Key Facts
Dr. Reddy's Laboratories Ltd - Key Employees
Dr. Reddy's Laboratories Ltd - Key Employee Biographies
Dr. Reddy's Laboratories Ltd - Major Products and Services
Dr. Reddy's Laboratories Ltd - History
Dr. Reddy's Laboratories Ltd - Company Statement
Dr. Reddy's Laboratories Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Dr. Reddy's Laboratories Ltd - Business Description
Business Segment: Global Generics
Overview
Performance
Business Segment: Other Operating Income
Performance
Business Segment: Others
Overview
Performance
Business Segment: Proprietary Products
Overview
Performance
Business Segment: PSAI
Overview
Performance
Geographical Segment: India
Performance
Geographical Segment: Others
Performance
Geographical Segment: Russia
Performance
Geographical Segment: United States
Performance
R&D Overview
Dr. Reddy's Laboratories Ltd - Corporate Strategy
Dr. Reddy's Laboratories Ltd - SWOT Analysis
SWOT Analysis - Overview
Dr. Reddy's Laboratories Ltd - Strengths
Dr. Reddy's Laboratories Ltd - Weaknesses
Dr. Reddy's Laboratories Ltd - Opportunities
Dr. Reddy's Laboratories Ltd - Threats
Dr. Reddy's Laboratories Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 06, 2021: Dr Reddy’s agrees to transfer rights of anti-cancer assets to Citius
Aug 03, 2021: Dr. Reddy’s announces the re-launch of over-the-counter naproxen sodium tablets USP, 220 mg, store-brand equivalent of aleve in the U.S. Market
Jul 27, 2021: Dr. Reddy’s announce Q1 FY22 Financial Results
Jul 27, 2021: Dr. Reddy’s Q1 FY22 financial results
Jul 27, 2021: Dr Reddys Laboratories Unaudited Financial Results For The Quarter Ended June 30, 2021
Jun 30, 2021: Indian pharma companies partner to trial molnupiravir for Covid-19
Jun 30, 2021: Dr. Reddy''s Laboratories Announces Filing of Annual Report on Form 20-F
Jun 16, 2021: Arbitration award: Dr Reddy’s asked to pay $46.25 mn to Hatchtech in US
May 14, 2021: Dr. Reddy’s Q4 & FY21 Financial Results
May 11, 2021: Dr. Reddy's Laboratories: Management changes
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Dr. Reddy's Laboratories Ltd - Key Facts
Dr. Reddy's Laboratories Ltd - Key Employees
Dr. Reddy's Laboratories Ltd - Key Employee Biographies
Dr. Reddy's Laboratories Ltd - Major Products and Services
Dr. Reddy's Laboratories Ltd - History
Dr. Reddy's Laboratories Ltd - Company Statement
Dr. Reddy's Laboratories Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Dr. Reddy's Laboratories Ltd - Business Description
Business Segment: Global Generics
Overview
Performance
Business Segment: Other Operating Income
Performance
Business Segment: Others
Overview
Performance
Business Segment: Proprietary Products
Overview
Performance
Business Segment: PSAI
Overview
Performance
Geographical Segment: India
Performance
Geographical Segment: Others
Performance
Geographical Segment: Russia
Performance
Geographical Segment: United States
Performance
R&D Overview
Dr. Reddy's Laboratories Ltd - Corporate Strategy
Dr. Reddy's Laboratories Ltd - SWOT Analysis
SWOT Analysis - Overview
Dr. Reddy's Laboratories Ltd - Strengths
Dr. Reddy's Laboratories Ltd - Weaknesses
Dr. Reddy's Laboratories Ltd - Opportunities
Dr. Reddy's Laboratories Ltd - Threats
Dr. Reddy's Laboratories Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 06, 2021: Dr Reddy’s agrees to transfer rights of anti-cancer assets to Citius
Aug 03, 2021: Dr. Reddy’s announces the re-launch of over-the-counter naproxen sodium tablets USP, 220 mg, store-brand equivalent of aleve in the U.S. Market
Jul 27, 2021: Dr. Reddy’s announce Q1 FY22 Financial Results
Jul 27, 2021: Dr. Reddy’s Q1 FY22 financial results
Jul 27, 2021: Dr Reddys Laboratories Unaudited Financial Results For The Quarter Ended June 30, 2021
Jun 30, 2021: Indian pharma companies partner to trial molnupiravir for Covid-19
Jun 30, 2021: Dr. Reddy''s Laboratories Announces Filing of Annual Report on Form 20-F
Jun 16, 2021: Arbitration award: Dr Reddy’s asked to pay $46.25 mn to Hatchtech in US
May 14, 2021: Dr. Reddy’s Q4 & FY21 Financial Results
May 11, 2021: Dr. Reddy's Laboratories: Management changes
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Dr. Reddy's Laboratories Ltd, Key Facts
Dr. Reddy's Laboratories Ltd, Key Employees
Dr. Reddy's Laboratories Ltd, Key Employee Biographies
Dr. Reddy's Laboratories Ltd, Major Products and Services
Dr. Reddy's Laboratories Ltd, History
Dr. Reddy's Laboratories Ltd, Other Locations
Dr. Reddy's Laboratories Ltd, Subsidiaries
Dr. Reddy's Laboratories Ltd, Joint Venture
Dr. Reddy's Laboratories Ltd, Key Competitors
Dr. Reddy's Laboratories Ltd, Ratios based on current share price
Dr. Reddy's Laboratories Ltd, Annual Ratios
Dr. Reddy's Laboratories Ltd, Annual Ratios (Cont...1)
Dr. Reddy's Laboratories Ltd, Annual Ratios (Cont...2)
Dr. Reddy's Laboratories Ltd, Interim Ratios
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Dr. Reddy's Laboratories Ltd, Key Facts
Dr. Reddy's Laboratories Ltd, Key Employees
Dr. Reddy's Laboratories Ltd, Key Employee Biographies
Dr. Reddy's Laboratories Ltd, Major Products and Services
Dr. Reddy's Laboratories Ltd, History
Dr. Reddy's Laboratories Ltd, Other Locations
Dr. Reddy's Laboratories Ltd, Subsidiaries
Dr. Reddy's Laboratories Ltd, Joint Venture
Dr. Reddy's Laboratories Ltd, Key Competitors
Dr. Reddy's Laboratories Ltd, Ratios based on current share price
Dr. Reddy's Laboratories Ltd, Annual Ratios
Dr. Reddy's Laboratories Ltd, Annual Ratios (Cont...1)
Dr. Reddy's Laboratories Ltd, Annual Ratios (Cont...2)
Dr. Reddy's Laboratories Ltd, Interim Ratios
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Dr. Reddy's Laboratories Ltd, Performance Chart (2017 - 2021)
Dr. Reddy's Laboratories Ltd, Ratio Charts
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Performance Chart (2017 - 2021)
Dr. Reddy's Laboratories Ltd, Ratio Charts
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021